CONCLUSIONS: Our study show that SRD5A2 hypermethylation in promoter regions, specifically at CpG#: -39 to CpG#: -2, a condition that favors estrogenic as opposed to an androgenic milieu in the prostate, is significantly associated with better survival in CRPC patients treated with ADT. Recognition of epigenetic modifications of SRD5A2, which affects the prostatic hormonal environment, may affect the choices and sequence of available therapies for management of CRPC.
INTRODUCTION AND OBJECTIVES: Prostate cancer (PCa) is
characterized by increased activation of the procoagulant protein, tissue factor (TF) that drive tumour progression. We now show that this process is modulated by GRP78 on the cell surface (cs). In PCa GRP78 is a endoplasmic reticulum-resident chaperone that localizes to the cell surface where it functions as a signaling molecule with antigenic properties. In response to csGRP78 presentation, PCa patients produce autoantibodies (AutoAbs) against the N-terminus of GRP78. AutoAbs:csGRP78 complex acts as a potent driver of tumor growth via upregulation of the unfolded protein response (UPR) and TF activity. We hypothesize that inhibiting the binding of anti-GRP78 AutoAbs to csGRP78 will supress UPR and TF activity. Here we describe a recombinant anti-GRP78 antibody (AEP8587) that competes with the binding of AutoAbs to csGRP78 and may act as a novel therapeutic antibody with antitumor activity.
METHODS: Changes in TF activity or UPR markers were evaluated in vitro in the PCa cell line DU145 following treatment with anti-GRP78 AutoAbs or co-treatment with either enoxaparin, a low molecular weight heparin (LMWH), or AEP8587. Protein expression of TF and UPR markers was determined using western blotting and qRT-PCR. TF activity was determined using a real-time continuous assay. AutoAbs were purified PCa patients (St. Joseph's Healthcare Hamilton).
RESULTS: Pre-prostatectomy PCa patients display high levels of anti-GRP78 AutoAbs (w60µg/ml), compared to healthy controls (w5µg/ml). Here, we show that anti-GRP78 AutoAb increases TF activation in vitro and leads to increased tumor progression in a DU145 xenograft model. In contrast, we show a co-treatment of anti-GRP78 AutoAb with either enoxaparin or AEP8587 completely abolishes the AutoAb-mediated increase in TF activity in vitro. Enoxaparin or AEP8587 co-treatment reversed the AutoAb effect on increased UPR markers.
CONCLUSIONS: We have identified anti-GRP78 AutoAb as a driver of PCa progression. Our results indicate that a recombinant antibody, AEP8587, can bind to csGRP78 and prevent the binding of anti-GRP78 AutoAbs. This represents a potential novel means to manage PCa progression. INTRODUCTION AND OBJECTIVES: Over 80% of advanced prostate cancer (PCa) patients develop bone metastases for which there is no cure. PCa lines have been used for the development of new therapies, however they do not fully represent PCa heterogeneity nor the bone metastatic disease. Thus, we established new patient-derived models for bone metastatic prostate cancer. We generated threedimensional (3D) organoids from our patient-derived xenograft (PDX) model and characterized their response to either dihydrotestosterone (DHT) or the anti-androgen, Enzalutamide.
METHODS: Intra-femoral PDX tumor cells were used to establish 3D organoids according to previously described protocols for prostate cancer. Culture medium was supplemented with 10% v/v fetal bovine serum (FBS) and AE 1nM DHT or AE10uM Enzalutamide in 0.1% v/v dimethyl sulfoxide (DMSO) for four weeks. Overall viability was quantified using luciferase-based viability assay. Changes to different types of multi-cellular masses were quantified as changes in cyst number, cyst lumen diameter, and spheroid area using the Keyence microscope and image analysis software. Statistical significance was determined using a student's t-test. Quantitative RT-PCR was performed for Prostate-Specific Antigen (PSA) and Prostate-Specific Membrane Antigen (PSMA). PSA immunohistochemistry (IHC) and immunofluorescence cytochemistry (IFC) for androgen receptor (AR), and cytokeratins 5 and 8 (CK5, CK8) were performed.
RESULTS: Enzalutamide treatment did not reduce overall viability of our PDX-derived 3D organoid cultures. Intriguingly, the PDO cultures consisted of heterogeneous cell populations that formed hollow cysts or spheroids. Treatment with DHT significantly increased the average cyst lumen diameter, cyst count as well as the spheroid area in (p < 0.05). Conversely, treatment with Enzalutamide significantly decreased the average cyst lumen diameter, cyst count and spheroid area (p < 0.05). Analogous structures were observed in the PDX tumors. Quantitative RT-PCR and PSA IHC showed that Enzalutamide reduced PSA expression but did not change PSMA expression.
CONCLUSIONS: The overall resistance of the PDX-derived 3D organoids (PDO) to Enzalutamide treatment mirrored the in vivo response of our bone metastatic prostate cancer PDX model. The heterogeneous populations of hollow cysts and spheroid clusters Vol. 201, No. 4S, Supplement, Monday, May 6, 2019 THE JOURNAL OF UROLOGY Ò e1179
